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Obesity is a risk factor for postmenopausal estrogen receptor alpha (ERα) 
positive (ER(+)) breast cancer. Molecular mechanisms underlying factors from plasma 
that contribute to this risk and how these mechanisms affect ERα signaling have yet to 
be elucidated. To identify such mechanisms, we performed whole metabolite and 
protein profiling in plasma samples from women at high risk for breast cancer, which led 
us to focus on factors that were differentially present in plasma of obese vs. non-obese 
postmenopausal women. These studies, combined with in vitro assays, identified free 
fatty acids (FFA) as circulating plasma factors that correlated with increased 
proliferation and aggressiveness in ER(+) breast cancer cells. FFA activated both the 
ERα and mTOR pathways and rewired metabolism in breast cancer cells. Pathway 
preferential estrogen-1 (PaPE-1), which targets ERα and mTOR signaling, was able to 
block changes induced by FFA and was more effective in the presence of FFA. 
Collectively, these data suggest a role for obesity-associated gene and metabolic 
rewiring in providing new targetable vulnerabilities for ER(+) breast cancer in 
postmenopausal women. Furthermore, they provide a basis for preclinical and clinical 
trials where the impact of agents that target ERα and mTOR signaling crosstalk would 
be tested to prevent ER(+) breast cancers in obese postmenopausal women.  
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STATEMENT of SIGNIFICANCE 
Findings show that obesity-associated changes in certain blood metabolites rewire 
metabolic programs in cancer cells, influence mammary epithelial cell tumorigenicity 
and aggressiveness, and increase breast cancer risk. 
INTRODUCTION 
The rate of increase in BMI is higher for women in the U.S. and percent of cancer 
cases attributable to excess body weight is twice as high for women compared to men  
(1,2). Sedentary lifestyle and western-style, fat- and sugar-rich diets, combined with low 
estrogen levels in postmenopausal women, aggravate this problem, making 
postmenopausal women more susceptible to weight gain, fat redistribution to abdominal 
areas, dyslipidemia, hypertension and insulin resistance, which are the major hallmarks 
of metabolic syndrome (3). In fact, almost 70% of postmenopausal women in the US are 
overweight or obese.  . A weight gain of 55 or more pounds from age 18 increases breast 
cancer risk by 50% (4). Being overweight after menopause increases ER(+) breast 
cancer risk by 70% (5-7). Eighty-two different studies including analysis of more than 
200,000 women with breast cancer showed that obesity increases mortality both in 
premenopausal and postmenopausal women (8). Obesity-associated cancers are a 
significant clinical problem and uncovering and targeting obesity-associated molecules 
and signaling pathways activated by these molecules may identify populations at risk 
and reduce breast cancer-related deaths. 
Systemic hyperlipidemia, hyperglycemia, insulin resistance, increased estrogen 
production by adipose tissue, and increased inflammation associated with obesity 
contribute to the risk and development of breast cancer (9). Obesity-associated factors 
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such as IGF1, adipokines, and cytokines modulate oncogenic PI3K and mTOR signaling 
pathways(10). Tumor-associated cholesterol-metabolites, such as 27-
hydroxycholesterol, also increased risk of breast cancer metastasis and worsen breast 
cancer outcomes (11-13). Yet, we still lack the information regarding other molecules 
from plasma that increase the breast cancer risk.  
Our aim in this study was to identify and test the impact of various circulating 
factors in blood associated with breast cancer risk.  Our hypothesis was that specific 
circulating metabolites and proteins , detectable in plasma, increase the risk of ER(+) 
breast cancer in obese postmenopausal women compared to their non-obese 
counterparts.  Using a multiple –omics approach we identified certain free fatty acids 
(FFA) that are relevant to obesity-associated breast cancer risk and uncovered ERα and 
mTOR pathway-dependent metabolic rewiring in breast cancer cells under conditions 
that mimic plasma from obese postmenopausal women.  We have previously described 
the identification and design of novel pathway preferential estrogens that modulate ERα 
and mTOR signaling crosstalk (14). One of these compounds, termed Pathway 
Preferential Estrogen 1 (PaPE-1), was initially identified in a screen of estrogen-like 
molecules that had lower affinity for the estrogen receptor, and stimulated extranuclear 
ER activity with limited effects on nuclear ER-target gene expression. PaPE-1 modulated 
extranuclear ER-initiated kinase signaling, particularly mTOR pathway, without inducing 
ERα recruitment to chromatin. In in vivo experiments, PaPE-1 treatment reduced 
ovariectomy-induced weight gain, blood triglyceride levels, and fat deposition in an ERα-
dependent manner, without stimulating the uterus or mammary gland, and displayed a 
pattern of metabolic tissue-selective activity that would be optimal for preventing breast 
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cancer in postmenopausal women by reducing fat accumulation in the body (14). In the 
current study, PaPE-1, was able to block free fatty acid-dependent changes in human 
breast cancer cells. Hence, we have uncovered a novel role for extranuclear-initiated 
ERα signaling in rewiring breast cancer cell metabolism in response to obesity-
associated factors in the plasma. Our findings provide a basis for preventing or inhibiting 
obesity-associated breast cancer by using PaPEs that would exploit new metabolic 
vulnerabilities of breast tumors in obese postmenopausal women.  
MATERIALS and METHODS 
Participants and Samples  
All studies were approved by the Indiana University Institutional Review Board 
(IRB protocol number 1011003097 and 1607623663). All research was carried out in 
compliance with the Helsinki Declaration. Donors provide broad consent for the use of 
their specimens in research. The written informed consent document informed the 
donor that the donated specimens and medical data were going to be used for the 
general purpose of helping to determine how breast cancer develops. It is explained in 
the written informed consent that the exact laboratory experiments are unknown at the 
time of donation, and that proposals for use of the specimens will be reviewed and 
approved by a panel of independent researchers before specimens and/or data are 
released for research purposes. Hematoxylin and eosin stained sections of the FFPE 
tissue of the identified donors were reviewed by pathologist to confirm the absence of 
histological abnormalities. In order to exclude or control confounding variables such as 
age, racial and ethnic background and menopausal status the subjects in the two 
cohorts, susceptible and healthy controls, were matched by selection of the comparison 
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group (healthy controls) with respect to the distribution of the above mentioned 
confounders in susceptible group. 
All studies were approved by the University of Illinois, Urbana-Champaign 
Institutional Review Board (IRB protocol number 06741). The Midlife Women’s Health 
Study is a longitudinal study on risk factors for hot flashes in women who are residents 
of the Baltimore metropolitan region, which includes Baltimore city and several of its 
surrounding counties (15).  This parent study, named the Midlife Women’s Health 
Study, was specifically designed to test the hypothesis that obesity is associated with 
hot flashes through mechanisms that involve early ovarian failure, altered estradiol 
levels, and selected genetic polymorphisms in steroidogenic enzymes and steroid 
hormone receptors.  We analyzed plasma samples from 37 non-obese and 63 obese 
postmenopausal women who were two to three years into menopause at the time of 
sampling. In addition, we analyzed plasma samples from 21 postmenopausal women 
who were obese at the initiation of the study and later lost weight.   
Plasma preparation 
Blood is drawn into the Plasma Separator tube (Vacutainer Venous Blood 
Collection Tubes: SST* Plasma Separation Tube, Fisher Scientific cat. #0268396) and 
gently mixed by inverting the tube 5 times. Forty-five minutes (±10 min.) after the blood 
has been drawn, the Plasma Separator Tube is placed into a minicentrifuge (Eppendorf 
centrifuge 5702) and centrifuged at 1200 rcf for ten minutes at room temperature. A 
repeater pipet is used to aliquot 600 µl of the plasma into each of five cryogenic vials. 
Samples are stored at -80 °C until use.  
Primary cell culture 
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Primary mammary epithelial cells were isolated from 10 cryopreserved breast 
biopsies of healthy donors as previously described (16,17). Briefly, cryopreserved tissue 
biopsies were thawed in a 100-mm petri dish containing 5 ml of culture medium. The 
tissue was minced using opposite scalpels and collected in a 15 ml tube containing 13 
ml digestion medium (Collagenase/Hyaluronidase, STEMCELL technologies, 
Cambridge, MA ). The digestion mixture was left in agitation on a tube rotator for 2-3 
hours at 37 °C.  After a centrifugation at 600Xg for 5 minutes and washing step with 
PBS the digested pellet was suspended in 3 ml of culture medium. The suspension is 
filtered through a 70 µm cell strainer and plated in a 60-mm petri dish containing a layer 
of irradiated MEF feeder cells (Applied StemCell, Milpitas, CA), and 2ul/ml Adenine 
(Sigma Aldrich, St. Louis, MO),  and 0.5ul/ml ROCK inhibitor (Y-27632, Enzo Life 
Sciences, Farmingdale, NY) are added to the culture media (18). Differential 
trypsinization was used to separate feeder and epithelial cells during passaging.  
Immunofluorescence Studies in Primary Mammary Epithelial Cell Cultures 
The primary epithelial cells (2.5x104) were plated into 8-well culture slides 
(Corning) and incubated at 37 °C for 18 hours. Upon incubation, cells are then fixed in 
cold methanol: acetone (1:1) and incubated at −20 ̊C for 15 min. After washing twice 
with PBS1X, cells were incubated with blocking buffer (PBS1X, 5% normal goat serum, 
0.1%TritonX-100) at RT for 1 hour. Cells were then incubated with the following primary 
antibodies anti-K14 (Biolegend#PRB-155P-100, polyclonal rabbit, 1:1000) and anti-
K18/8 (Cell Signaling, mouse, 1:100) over night at 4°C. After washing with PBS1X, the 
cells were incubated with fluorescent anti-mouse (Alexa Fluor 488 anti-mouse and 
Alexa Fluor 594 anti-rabbit) secondary antibodies (1:500, ThermoFisher Scientific) and 
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DAPI (1:1000) for two hours at room temperature. Both the primary and secondary 
antibodies are diluted in Antibody diluent (Dako, Agilent). Finally, the cells were washed 
with PBS1X and slides were mounted with a cover glass. Images were acquired using 
an Olympus Fluoview 1000 confocal microscope. The number of double positive cells 
and the total number of cells (DAPI) present in a determined area of each of the 14 
primary epithelial cell cultures were counted. The percentage of double positive 
measured as 100%X (Number of K14+K18+/Number of DAPI+). 
Cell Culture, Ligand Treatments, siRNA and Reagents 
MCF-7, T47D, BT474 and MDA-MB-231 cells were obtained from American Type 
Culture Collection (ATCC).  ERα expression was verified by Q-PCR, Western blotting and 
gene expression. Cell proliferative response to E2 and other estrogens was monitored 
regularly. Each cell line was monitored for mycoplasma contamination regularly using 
Mycoplasma Detection Kit (VWR, 89510-164). MCF-7, T47D and BT474 cells were grown 
in minimal essential medium (MEM) (Sigma, St Louis, MO), supplemented with 5% calf 
plasma (HyClone, Logan, UT), and 100 µg/ml penicillin/streptomycin (Invitrogen, 
Carlsbad, CA). MDA-MB-231 cells were grown in Leibowitz’s medium with 10% calf 
plasma (HyClone), and 100 µg/ml penicillin/streptomycin (Invitrogen). PaPE-1 was 
synthesized as described (14). All the FFAs; oleic acid (OA), palmitic acid (PA), stearic 
acid (SA) and linoleic acid (LA), used in the cell assays were purchased from Sigma-
Aldrich. The FFAs were solved in a small amount of DMSO and brought to desired 
concentration by adding ethanol. Fulvestrant, RAD001 (mTOR inhibitor), 4-OH-
Tamoxifen, Etomoxir (E1905), 2-DG (D8375), Oligomycin (O4876), Rotenone (R8875) 
and UK5099 (PZ0169) were obtained from Sigma-Aldrich. AZD6244 (MEK inhibitor) was 
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obtained from Selleckchem. For siRNA experiments, MCF-7 cells were seeded on 96-
well plates at 2x103/well concentration in corresponding growth media containing 5% FBS 
and no antibiotics. Human CD36 (SC-29995),PPARα (SC-36307) and SREBP-1 (sc-
36557) siRNAs were obtained from Santa Cruz Biotechnology (Santa Cruz Biotechnology 
Inc., Santa Cruz, CA) and prepared according to manufacturer’s protocol. Cells were 
transfected with siRNAs in OptiMEM™ treatment media (Gibco, Gaithersburg, MD) 
without antibiotics by using DharmaFECT transfection reagent (Dharmacon Inc., 
Lafayette, CO). Control cells were treated with transfection reagent only. All cells were 
incubated in 37°C, 5% CO2-containing incubator for 48 hours. (mRNA accession codes 
of CD36 siRNAs are NM_000072, NM_001001547, 
NM_001001548, NM_001127443, NM_001127444,  mRNA accession codes of PPARα 
siRNAs are NM_001001928, NM_005036 and mRNA accession codes of SREBP-1 
siRNAs are NM_001005291, NM_001321096, NM_004176). After 48 hours, cells were 
treated with 10-7 M OA or PA and 10-6 M PAPE-1 individually and in combination every 
three days. Cell viability was measured by adding 10% WST-1 reagent/well at the end of 
7th day. Each experiment was repeated at least twice with six technical replicates. A one-
way ANOVA test was used to test statistical significance of MCF-7 cell viability difference 
due to OA or PA treatment with or without siRNA for indicated factors. To validate protein 
knockdown, MCF-7 cells were seeded on 6-well plates at 2x105/well in corresponding 
growth media containing 5% FBS and no antibiotics. Human CD36 (SC-29995), SREBP-
1 (sc-36557) and PPARα (SC-36307) siRNAs were obtained from Santa Cruz 
Biotechnology (Santa Cruz Biotechnology Inc., Santa Cruz, CA) and prepared according 
to manufacturer’s protocol. Cells were transfected with siRNAs in OptiMEM™ treatment 
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media (Gibco, Gaithersburg, MD) without antibiotics by using DharmaFECT transfection 
reagent (Dharmacon Inc., Lafayette, CO). Control cells were treated with transfection 
reagent only. All cells were incubated in 37°C, 5% CO2-containing incubator. After 48h 
hours, cells were collected and protein expressions were assessed by western blotting. 
Each experiment condition was repeated at least twice and the statistical significance of 
the results were analyzed by a one-way ANOVA test.  
Cell Proliferation, Migration and mTOR pathway Activation Assays 
For cell proliferation experiments, cells were seeded at 500 cells/well in triplicate 
(unless otherwise stated) in 96-well plates (19). The cells were treated with Veh (0.1% 
ethanol) or indicated doses of ligands and inhibitors at the concentrations indicated on 
the second day and 5th day.  On the 7th day, cell proliferation was assessed using WST-
1 reagent (Roche) following the instruction. The number of plasma samples assayed 
(35 obese and 35 non-obese plasma samples) was determined based on the availability 
of the plasma samples. The day after seeding the cells, treatments were done using the 
plasma samples that were diluted 1:3 in growth media. For experiments involving 
estrogens, media without plasma was added Veh (0.1% EtOH) or PaPE-1, Fulvestrant 
or 4-OH-Tamoxifen to the final concentration of 1.5 µM. 100 µl of the inhibitor-media mix 
was added to each well. Next 50 µl of media was added to bring the final concentration 
of plasma to 30% and inhibitor concentration to 1 µM. Plasma from same individuals 
were used in motility and mTOR pathway activation assays. Cell migration was assayed 
in BT474 cells that were seeded at a density of 5X105 cells/mL in 96 well FluoroblockTM 
plates in triplicate. 24h after treatment with the media containing 30% plasma from each 
individual, cell number on the bottom part of the well was monitored by CellTracker dye 
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using the Cytation 5 software Gen5. mTOR pathway activation was assayed in MCF-7 
cells. MCF-7 cells were seeded at 10,000 cells/well in 96 well black-sided clear bottom 
plates.  Cells were treated with the media containing 30% plasma for 45 min and then 
crosslinked using 4% paraformaldehyde for 30 min at room temperature.  After 1 hour of 
blocking using Odyssey blocking buffer at room temperature, cells were incubated with 
1:200  p-S6 (Ser235/236) (#2211, Cell Signaling) antibody overnight at 4˚C. After three 
times ten minutes PBS-0.1% Tween washes, cells were incubated in 1:500 goat anti-
rabbit IRdye 800cw (Licor biosciences) for one hour at room temperature. After three 
times ten minutes PBS-0.1% Tween and three times ten minutes PBS washes cells 
were incubated with DRAQ5™ Fluorescent Probe for signal normalization for 30 
minutes at room temperature. After three PBS washes, the signal was detected using 
LICOR Odyssey In-cell Western Module.          
Western Blotting 
Western blot analysis used specific antibodies for β-actin (Sigma Aldrich), p-Akt 
(Ser473) (#4060), total Akt (#9272), p-ERK1/ERK2 (Thr202/Tyr204) (#4370), total 
ERK1/ERK2 (#9102), Phospho-p70 S6 Kinase (Thr421/Ser424) (#9204), Phospho-p70 
S6 Kinase (Thr389) (#9205), p70 S6 Kinase (49D7)(#2708), p-4EBP1(T37/46) (#2855) 
and total 4EBP1 (#9644) (Cell Signaling). MCF-7 cells were seeded at 500.000 cells in 
10 cm dishes in growth media. Next day, cells were treated with Veh, 100 nM OA, PA, 
LA or SA for indicated times. Cell lysate was prepared using RIPA buffer. Samples were 
sonicated three times 10 seconds to shear the DNA.  10 µg protein was loaded onto 
10% SDS gels. Antibodies were used at 1:500 except for β-actin (1:5000). Proteins 
were visualized using Odyssey LICOR imaging system.  
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ChIP-Seq Analysis and Verification using qPCR 
The ChIP-Seq analysis was performed as described previously (14,20). ERα-
DNA or IgG-DNA complexes were immunoprecipitated using ERα specific HC-20 
antibody (Santa Cruz Biotechnology). The ChIP DNA from is three pooled biological 
replicates. Libraries were prepared according to Illumina Solexa ChIP-Seq sample 
processing, and single read sequencing was performed using the Illumina HiSeq 2000. 
Sequences generated were mapped uniquely onto the human genome (hg18) by 
Bowtie2 . The MACS (Model-based Analysis of ChIP-Seq) algorithm was used to 
identify enriched peak regions (default settings) with a p-value cutoff of 6.0e-7 and FDR 
of 0.01, as we have described . To verify the identified binding sites from ChIP-Seq 
findings, ChIP-qPCR using the isolated DNA was performed using the primers designed 
to target the binding sites at PgR (chr11:100,904,522-100,905,458), CISH 
(chr3:50,642,336-50,643,191), and SREBP1c (chr17:17,743,329-17,743,912).  
RNA-Seq Transcriptional Profiling  
For gene expression analysis, total RNA was extracted from three biological 
replicates for each ligand treatment using Trizol reagent and further cleaned using the 
RNAeasy kit (QIAGEN). MCF-7 cells were treated with Veh (0.1% EtOH), 100 nM PA, 
LA or SA, or 100 nM OA in presence or absence of one μM PaPE-1 for 24 h. Once the 
sample quality and replicate reproducibility were verified, samples from each group 
were subjected to sequencing. RNA at a concentration of 100 ng/µL in nuclease-free 
water was used for library construction. cDNA libraries were prepared with the mRNA-
TruSeq Kit (Illumina, Inc.). Briefly, the poly-A containing mRNA was purified from total 
on July 7, 2020. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2849 
13 
 
RNA, RNA was fragmented, double-stranded cDNA was generated from fragmented 
RNA, and adapters were ligated to the ends.  
The paired-end read data from the HiSeq 2000 were processed and analyzed 
through a series of steps. Base calling and de-multiplexing of samples within each lane 
were done with Casava 1.8.2. FASTQ files were trimmed using FASTQ Trimmer 
(version 1.0.0). TopHat2 (version 0.5) was employed to map paired RNA-Seq reads to 
version hg19 of the Homo sapiens reference genome in the UCSC genome browser in 
conjunction with the RefSeq genome reference annotation. Gene expression values 
(raw read counts) from BAM files were calculated using the StrandNGS (version 2.1) 
Quantification tool.  Partial reads were considered and the option of detecting novel 
genes and exons was selected.  Default parameters for finding novel exons and genes 
were specified.  The DESeq normalization algorithm using default values was selected. 
Differentially expressed genes were then determined by fold-change and p-value with 
Benjamini and Hochberg multiple test correction for each gene, for each treatment 
relative to the vehicle control. We considered genes with fold-change >2 and p-value < 
0.05 as statistically significant, differentially expressed. 
OLINK Protein biomarker and whole metabolite profiling assays  
All the samples from human studies were handled and analyzed in accordance 
with UIUC IRB protocol #06741. Written informed consent was obtained from all 
subjects. 10 µl of plasma samples from Komen Tissue Bank and Midlife Women’s 
Health studies were submitted to OLINK biosciences for cancer and inflammation 
biomarker analysis. 50 µl of plasma samples from both studies and MCF-7 cell pellets 
that were treated with Veh, 100 nM OA, 1 μM PaPE-1+OA for 24 h were submitted to 
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the Metabolomics Center at UIUC. GC/MS whole metabolite profiling was performed to 
detect and quantify the metabolites by using Gas chromatography-mass spectrometry 
(GC/MS) analysis. Metabolites were extracted from 50 µl of plasma according to Agilent 
Inc. application notes. The hentriacontanoic acid was added to each sample as the 
internal standard prior to derivatization. Metabolite profiles were acquired using an 
Agilent GC-MS system (Agilent 7890 gas chromatograph, an Agilent 5975 MSD, and an 
HP 7683B autosampler). The spectra of all chromatogram peaks were evaluated using 
the AMDIS 2.71 and a custom-built database with 460 unique metabolites. All known 
artificial peaks were identified and removed prior data mining. To allow comparison 
between samples, all data were normalized to the internal standard in each 
chromatogram.  Metabolomics data with sample class annotations (healthy and 
susceptible) were uploaded to the Statistical Analysis tool of MetaboAnalyst software 
version 4.0 (21). Features with more than 50% missing values were removed. Data 
were normalized based on values from “Healthy” samples. Data were log transformed 
and scaled using Auto scaling feature. VIP scores for top 25 metabolites that 
discriminate between healthy and susceptible individuals were calculated and displayed 
using the Partial Least Squares-Discriminant analysis tool. Heatmap of class averages 
of 25 metabolites was generated using Heatmap feature using default options for 
clustering and restricting the data to top 25 metabolites ranked by t-test. Heatmap for 
abundance of each metabolite and association with class, menopausal status and BMI 
were generated using Cluster3 and visualized using Java Treeview.  We calculated the 
correlation between all identified circulating factors (metabolite and protein) using the 
Pearson correlation coefficient using R software (R Core Team, 2015). R Code to 
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calculate correlation coefficients and p-values are available upon request. Correlation 
coefficients and p-values were clustered using Cluster3 software and visualized using 
Treeview Java tool. 
Seahorse Metabolic Profiling Experiments: 
The metabolic profiling was performed using MCF-7 cells following the instruction 
of Seahorse cell profiler, glycolytic stress and mitochondrial stress kits. 30,000 cells/well 
were seeded in XF 8-well cell culture mini plates in 80 μl of growth medium. This 
number was chosen based on achieving close to 100% confluence on the day of 
Seahorse assay run. Experiments were performed in triplicate at least twice. After 24 
hours incubation at 37oC in 5% CO2, Veh (0.1 % EtOH) or 100 nM each FFA with and 
without 1 μM PaPE-1, RAD001 or AZD6244 treatment was added to the cells in 200 μl 
of growth medium.  After 24 hours treatment, the medium from each well was carefully 
removed and replaced with 180 μl of assay medium. The assay medium was freshly 
prepared, and the pH was carefully adjusted right before each assay. The mixture of 
substrate and plate loading was done by strictly following the instructions for each 
assay: XFp cell energy Phenotype test and Mitostress test. The oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) were measured using Seahorse 
XFp analyzer. The data were analyzed by Wave software. In parallel, a duplicate of 
each plate was used for cell counting to monitor cell number changes after 24hours of 
treatment with FFAs or inhibitors.  
CignalTM Finder 45-Pathway and Cignal TF Reporter Assay  
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Cignal Finder reporter arrays or individual Cignal TF reporter assays were used 
to measure the activation of 45 different pathways in MCF-7 cells. Cells were seeded in 
CignalTM Finder 96-well plates at a density of 40000 cells/well in growth medium. 
Reverse transfection was used to introduce the pathway reporter into cells, following the 
manufacturer’s protocol. Briefly, to each well of the plates, 50 μl OptiMEM was added to 
resuspend the DNA construct. Then 50 μl of diluted Addgene transfection reagent, as 
suggested in the protocol, was added to the mixture. Cells were resuspended in 
OptiMEM with 10% of fetal bovine plasma and 0.1 mM NEAA. Then 50 μl of the cell 
suspension was added to each well and mixed well with the DNA construct as well as 
the transfection reagent. The cells were incubated at 37 oC / 5% CO2 for 24 hours. The 
cells were treated with Veh, 1 μM PaPE-1, 100 nM OA and OA+PaPE-1 in growth 
medium for 24 h.  Immediately after the treatment, luciferase activities were determined 
by using a Dual-Luciferase reporter assay system from Promega. Briefly, the treatment 
medium was removed carefully from each well, and the cells were rinsed in PBS. After 
removing the PBS, 20 μl lysis reagent was added to each well, and the plate was 
incubated for 15 minutes. Then, 100 μl Luciferase assay reagent II (LAR II) was added 
to each well, and the luminescent signal was read immediately using Cytation 5 plate 
reader. After quantifying the firefly luminescence, 100 μl Stop & Glo reagent was added 
to the same sample following the measurement of luminescent signal. Experiments 
were repeated twice with duplicates. Transcription activity (Luciferase signal/Renilla 
signal) was calculated and all the data were plotted. 
Statistical Analyses  
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Data from in vitro cell line studies were analyzed using either a one-way analysis 
of variance (ANOVA) model to compare different ligand effects or a two-way-ANOVA 
model to compare FFA, inhibitor or siRNA effects. For every main effect that was 
statistically significant at p<0.05, pairwise t-tests were conducted to determine which 
ligand or inhibitor treatment levels were significantly different from each other. For these 
t-tests, the Bonferroni correction was employed to control the experimentwise type I 
error rate at α=0.05 followed by Bonferroni post hoc test using GraphPad Prism version 
6 for Windows, (GraphPad Software, La Jolla California USA, www.graphpad.com). All 
the values for all the experiments were plotted.  
Data Availability 
RNA-Seq data files are deposited under the accession number GSE114372 in 
GEO database and will become publicly available upon online publishing of the 
manuscript. Metabolomics, ChIPSeq and OLINK analysis datasets will be available from 
investigators upon request.  
RESULTS 
Identification of plasma factors from breast cancer susceptible women 
Since obese postmenopausal women have increased ER(+) breast cancer risk, 
we characterized the molecular changes associated with increased body mass index 
(BMI) and luminal or basal properties of the normal human mammary tissue from obese 
vs. non-obese women. Primary mammary epithelial cells were isolated from seven 
healthy (BMI<25) and eight obese (BMI>30) subjects. As previously described, basal-
like tumor cells, or triple negative breast cancers, may possess a high degree of 
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plasticity, allowing them to transition between basal, progenitor, and luminal states. 
These cells express basal keratins, such as K5 and K14, often together with luminal 
keratins such as K8 and K18 consistent with their plasticity (22).  A recent study by  Granit 
et al showed that most tumors contained a majority of cells expressing the luminal marker 
K18 (>50% in 36 of 45 tumors); as well as cells that co-expressed K18 and K14 (present 
in 38 of 45 tumors) Moreover, they demonstrate that  K18+K14+ cells possess enhanced 
tumorigenicity (22). Formation of colonies that contain cells of luminal or basal lineage 
was followed by keratin 8/18 and keratin 14 staining (Figure 1A). Samples were derived 
from seven non-obese (BMI<25) and eight obese (BMI≥30) subjects. Epithelial cell 
cultures from five out of eight (71%) obese women showed a reduced number of luminal 
cells and increased presence of cells in an undifferentiated state (K18 and K14 co-
staining) as compared to those from donors with BMI less than 30. We found a significant 
increase in the percentage of K14/K18 costained cells in obese women-derived cell 
cultures (mean±SEM=3.08 ±1.1) as compared with normal weight-derived cells (mean ± 
SEM=0.31±0.3) (Figure 1A). These results suggest an association between high BMI 
and presence of cancer precursor cells in the breast. To examine the association of BMI 
and breast cancer risk, we utilized data from a cohort of postmenopausal healthy controls 
(Healthy) and individuals who were clinically healthy at the time of data collection but 
later had a diagnosis of breast cancer (Susceptible) (N=40 pairs). In order to exclude or 
control confounding variables such as age, and racial and ethnic background, the 
subjects in the two cohorts were matched by selection of the comparison group (healthy 
controls) with respect to the distribution of the above mentioned confounders. BMI of 
paired individuals from susceptible group was higher compared to that of healthy 
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individuals (p=0.04) (Figure 1B). We also analyzed plasma samples from 29 healthy 
and 30 breast cancer susceptible individuals who were clinically healthy at the time of 
plasma collection but later had a diagnosis of breast cancer. We performed OLINK 
biomarker analysis for a panel of inflammation and cancer-related proteins. This analysis 
showed that several inflammation-associated factors (CD160(23), CD27(24), IL-12B(25) 
and TNFRSF19 (26)) and cancer biomarkers (hK8 (27), Nectin4(28), KLK13(29) and 
CTSV(30)) were correlated with BMI only in breast cancer susceptible individuals, but 
not in healthy controls (Figure 1C). In addition, two breast cancer-associated proteins in 
the plasma, SYND1/SCD1 (31) and TNFRSF6b (32), had significantly elevated 
normalized protein expression (NPX) scores in susceptible women than healthy women 
(Figure 1D). Furthermore, by using whole metabolomics analysis and Metaboanalyst 
software we identified top 25 plasma metabolites that discriminated between healthy and 
susceptible postmenopausal women, and therefore indicative of breast cancer risk 
(Figure 1E). This analysis showed that postmenopausal women who developed breast 
cancer had significantly higher levels of lipolysis byproducts, FFAs, including oleic acid 
(OA), palmitic acid (PA), linoleic acid (LA), stearic acid (SA) and arachidonic acid (AA), 
and glycerol in their plasma as compared to healthy controls (Figure 1F, 
Supplementary Figure 1).  
Validating plasma factors associated with obesity 
In obese individuals plasma FFA and glycerol concentrations are higher due to 
adipose tissue lipolysis (10). Since obesity and increased body fatness are established 
risk factors for postmenopausal ER(+) breast cancer, we focused our analysis on the 
contribution of FFAs to breast cancer cell properties (33). We measured the circulating 
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FFAs increased in susceptible individuals in an independent cohort including 37 non-
obese and 63 overweight and obese (BMI>25) postmenopausal women from the “Midlife 
Women’s Health Study”. Plasma samples were collected from cancer-free women, 2-3 
years after onset of menopause (15). Whole metabolite profiling was conducted for these 
100 samples (Figure 2A). The analysis revealed that plasma metabolite composition 
stratified the samples based on the women’s BMI. Due to the lack of medical follow-up 
for this study, we did not have the data of breast cancer incidence. Therefore, to 
determine the impact of BMI on cancer cell properties, we evaluated the effect of the 
plasma samples on cancer cell viability in ERα+ breast cancer cells, MCF7 and T47D, 
and ERα-, MDA-MB-231 cells (Figure 2B). Cell viability increase was observed when 
ERα+, but not ERα- cells were treated with plasma from obese individuals. There was a 
statistically significant linear correlation between in vitro cell proliferation and plasma 
donor’s BMI, but not with estradiol, testosterone, or progesterone levels 
(Supplementary figure 2A and B).  
Treatment with plasma from obese women stimulated both BT474 cell line motility 
and mTOR pathway activation in MCF-7 cells, suggesting a promotion of the aggressive 
properties of the breast cancer cells (Figure 2C). Since the original sample set derives 
from cancer-free women, we measured the levels of several established circulating 
biomarkers of breast cancer such as lower phenylalanine, glutamate and isoleucine 
levels, to verify the ability of any newly identified molecules of predicting the breast 
cancer outcome (34-36). Plasma samples increasing MCF-7 cell viability showed also 
lower level of the known metabolic cancer biomarkers compared with plasma samples 
associated with a lower MCF-7 proliferation (Supplementary Figure 2C). Hence, 
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together, the evaluation of cell viability, motility, and mTOR pathway activation was 
informative of the breast cancer outcomes. Plasma from overweight or obese women 
contained higher levels of FFAs similar to those increased in susceptible subjects 
(Figure 2A). In addition, MCF-7 cell viability increased with increasing plasma 
concentration of OA (p<0.0001), PA (p=0.0006), LA (p=0.0001) and AA (p=0.002). Even 
though there was a trend for SA (p=0.09) the correlation did not reach significance 
(Figure 2D). In the “Midlife Women’s Health Study”, 21 individuals who were obese at 
the beginning of the study had later lost a significant amount of weight. We monitored 
circulating FFA levels in these subjects and found significant reduction in all five FFAs 
upon weight loss when compared with their initial samples (Figure 2E and F).  
FFAs induces gene expression changes in breast cancer cells that are blocked by 
PaPE-1 
To study the impact of FFAs on breast cancer cells, we performed RNA-Seq 
analysis in MCF-7 breast cancer cells treated with Vehicle (Veh) or 100 nM of each FFAs; 
oleic acid (OA), linoleic acid (LA), palmitic acid (PA) and stearic acid (SA) (Fig. 3A). Each 
of the FFAs regulated common as well as different groups of genes (Figs. 3B, 3C and 
3D). Since plasma from obese patients increased cell viability (Fig. 2B) and mTOR 
pathway activation (Fig. 2C) in ER(+) breast cancer cells, we further investigated the 
mechanism of FFAs action using a novel class of compounds, pathway preferential 
estrogens (PaPEs). In our previous studies, we showed that PaPEs modulated ERα-
mTOR pathway crosstalk and prevented lipid deposition in the liver in mice (14). OA is 
one of the FFAs with highest blood concentration in breast cancer patients and was 
found to be released in highest amounts from the neighboring adipose tissue of 
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mammary epithelial cells upon lipolysis (37-39). Thus, to identify gene expression 
changes associated with FFA-induced ERα and mTOR pathway modulation, we treated 
MCF-7 cells with vehicle (Ctrl), 100 nM OA, and 100 nM OA in the presence of 1µM 
PaPE-1 (Figure 3E). The two treatments regulated a substantial number of different 
genes while also similarly affected overlapping genes (Figure 3F). PCA analysis shows 
the appreciable differentiation in gene regulation among the three treatments (Figure 
3G). In cluster 1 (C1), OA upregulated about 350 genes, and activation of 76% of these 
upregulated genes was blocked by PaPE-1. On the other hand, in cluster 2 (C2), about 
500 genes were downregulated by OA, and PaPE-1 was able to restore expression of 
about 60% of these genes (Figure 3E and H). GO term analysis showed that OA 
upregulated those genes that were involved in glycolysis, energy reserve metabolic 
process and epithelial cell migration. On the other hand, OA treatment downregulated 
those genes that were involved in glutathione and fatty acid metabolism, cell-cell 
adhesion and inhibitors of epithelial cell proliferation (Figure 3I).                 
FFAs activate mTOR and PI3K pathway 
Since plasma from obese individuals also increases mTOR pathway activation 
(Figure 2C) and OA upregulated gene sets associated with mTORC1 signaling and PI3K 
Pathway (Figure 4A), a pathway activation assay was performed to measure activation 
of mTOR pathway downstream targets P70S6K, and 4EBP1, Akt and ERK1/ERK2 when 
cells were treated with individual FFAs (Figure 4B). The western blots showed robust 
and consistent activation of mTOR pathway from OA, PA, LA, and SA treatments as 
evidenced by increased p70S6K phosphorylation as early as 15 minutes of FFA 
treatment (Figure 4B). Longer stimulation with FFAs showed a more robust activation of 
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mTOR pathway. ERK1/ERK2 activation was early and transient as its signal at 45 and 
90 min stimulation return to the baseline (Time 0) level. Fold change of phosphorylation 
relative to Vehicle treated samples varied by each FFA treatment (Figure 4B, 
Supplementary Figure 3).  FFA-dependent activation of both mTOR and MAPK 
pathway downstream targets were inhibited by mTOR inhibitor RAD001. However, MEK 
inhibitor AZD6244 only blocked phosphorylation of ERK1 and ERK2 (Figure 4C).    
FFAs induce cell proliferation in an ERα- and CD36-dependent manner  
OA treatment decreased expression of inhibitors of epithelial cell proliferation 
(Figure 3I) and increased expression of gene sets involved in cell proliferation when 
compared to control samples (Figure 5A). Expression of cell cycle genes regulating 
transition of the cell through mitotic phases is upregulated by OA (Figure 5A). OA and 
PA treatments significantly increased cell viability. However, when co-treated with PaPE-
1, the effect of FFAs are markedly reduced (Figure 5B).  To confirm that OA increased 
cell proliferation occurred through ERα and mTOR pathways, a cell viability assay was 
performed with OA treatments in the presence of Fulvestrant (Fulv), an ERα antagonist, 
and RAD001, an mTOR pathway inhibitor and PaPE-1. All of the tested agents blocked 
OA-induced cell proliferation, revealing the dependence of the OA-induced cell 
proliferation on the ERα and mTOR pathways (Figure 5C). To evaluate whether also 
plasma from obese individuals induced MCF-7 cell proliferation through ERα and mTOR 
pathways, cell proliferation assays with plasma samples were performed in the presence 
of 4-OH-tamoxifen (4-OH-Tam), Fulv, and PaPE-1. Notably, PaPE-1 was the most 
effective agent in inhibiting plasma-induced proliferation of MCF-7 cells (Figure 5D left 
panel). However, in standard cell culture conditions with 5 % FBS, 4-OH-Tam and Fulv 
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showed a stronger inhibition on cell proliferation than PaPE-1 (Figure 5D right panel). 
These results suggest that treatment with the plasma from obese individuals makes 
MCF-7 cells more vulnerable to the growth inhibitory effect of PaPE-1. Increase in MCF-
7 cell viability upon OA and PA treatments was blocked in the cells knocked down for 
CD36, a membrane protein that imports FFAs to the cell (Figure 5E). This data indicates 
that FFAs need to be transported inside the cell to stimulate cell proliferation. 
FFA treatment induces metabolic reprogramming in breast cancer cells 
Gene expression analysis (Figure 3) pointed out a potential change in metabolic 
pathways in MCF-7 cells upon OA exposure (Figure 6A). Metabolomics analysis of 
MCF-7 cells showed that after OA treatment, glycolysis metabolites were overall 
increased. Metabolites in the fatty acid biosynthetic pathways were down-regulated 
suggesting a negative feedback loop due to high levels of extracellular OA (Figure 6B). 
OA also downregulated many of the TCA cycle metabolites except malate and fumarate, 
suggesting an increase in malate shunt from the cytosol (Figure 6B). Cell metabolic 
phenotyping assays were performed, which revealed that in the presence of OA, the 
cells adopted an energetic phenotype and coped with the metabolic stress better by 
increasing their aerobic and glycolytic metabolic potential. The cells were more glycolytic 
and their mitochondrial metabolism was increased but PaPE-1 treatment was able to 
reverse OA-induced glycolytic and aerobic respiration (Figure 6C). There was a 
statistically significant OA-dependent increase in basal and maximal respiration and ATP 
production, which were reduced by PaPE-1 (Figure 6D). Inhibition of MAPK and mTOR 
pathways using small molecule inhibitors reduced OA-induced changes in mitochondrial 
respiration (Figure 6E). To understand the role of metabolism pathways in OA-induced 
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cell proliferation, cells were treated with OA in addition to Etomoxir (a fatty acid oxidation 
inhibitor), 2-Deoxy-D-glucose (2-DG, a glycolysis inhibitor), Oligomycin (an ATP 
synthase inhibitor), Rotenone (an inhibitor of mitochondrial respiration), and UK5099 (an 
inhibitor of mitochondrial pyruvate transporter). All inhibitors blocked the effects of OA 
indicating glycolysis and mitochondrial respiration as key pathways targeted by OA 
(Figure 6F).  
FFA treatment induces recruitment of ERα to chromatin 
To test if any of the gene expression changes induced by OA treatment occurs 
through direct ERα recruitment to chromatin, a ChIP-Seq experiment was performed. 
ERα is recruited to novel chromatin sites upon OA treatment and most of this recruitment 
is blocked by PaPE-1 treatment (Figure 7A). This ERα recruitment pattern was verified 
to various sites was verified, including to the classic ERα bind sites of for PgR, CISH, 
and SREBP-1, the last being a regulator of FA production (Figure 7B). To understand 
the nature of ERα recruitment to chromatin in the presence of OA, we further analyzed 
the OA-induced ERα binding sites (Figure 7A and C). This resulted in four main clusters 
that were named C1, C2, C3, and C4 (Figure 7C). Transcription factor binding motif 
enrichment analysis was performed using Seqpos tool from Cistrome/Galaxy. 
Interestingly, none of the clusters, except C2, had any enrichment of EREs, suggesting 
a potential tethering mode of recruitment for ERα to these sites (Figure 7C). 
Transcriptional activity of some of the previous factors were analyzed with luciferase-
based system called Cignal finder assay (Figure 7D). Consistent with transcription factor 
binding site analysis (Figure 7C), exposure to OA significantly increased the 
transcriptional activities of PPAR, LXR, RXR and EGR (Figure 7D). PPARα and 
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SREBP1 target genes, regulating FFA metabolism, are upregulated when treated with 
OA and result in a significant increase in cell proliferation (Figure 7E). Knockdown of 
PPARα and SREBP1 in MCF-7 cells blocked cell proliferation upon OA and PA 
treatments (Figure 7F). These analyses suggest that ERα recruits and collaborates with 
these nuclear receptors to regulate gene expression, resulting in changes that are 
essential for metabolic processes and survival of breast cancer cells. 
DISCUSSION 
Our study provides direct evidence for the impact of circulating obesity-associated 
factors, with a focus on free fatty acids from plasma, on ERα-mTOR signaling crosstalk 
in breast cancer.  Our combined –omics approach has highlighted gene, metabolite and 
transcription factor activity changes that are modulated by circulating factors from blood 
and for the first time describes obesity-associated metabolic rewiring of breast cancer 
metabolism related to disease risk that provides new targetable vulnerabilities that we 
have investigated. We showed that circulating FFA levels are higher in postmenopausal 
women with high BMI and high breast cancer risk. Circulating FFAs are taken up into cells 
in a CD36-dependent manner, which results in activation of mTOR and MAPK signaling 
and ERα recruitment to chromatin to increase transcriptional activity of factors that 
regulate cancer cell metabolism. Overall, these upstream events increase mitochondrial 
respiration, cell proliferation and aggressiveness for breast cancer cells (Figure 7G). 
Obesity causes systemic changes in the body and modifies plasma composition 
that enables breast cancer cells to thrive in an energy source-abundant, proinflammatory 
environment.  Several studies show that obese patients are more likely to present with 
advanced-stage disease, derive less benefit from adjuvant systemic therapy, are more 
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likely to develop distant metastases, and die from breast cancer more often than normal 
weight or underweight patients(40-42). Kerlikowske found that heavily obese (body mass 
index ≥35.0 kg/m2) postmenopausal women not taking HRT had increased odds ratio for 
DCIS (OR = 1.46) relative to normal weight women after adjustment for race, ethnicity, 
age, mammography use, and registry (43). A recent report by Hao et al showed that 
circulating A-FABP released by adipose tissue directly targeted mammary tumor cells, 
enhancing tumor stemness and aggressiveness (44). 
Previous studies of cancer biomarkers used single metabolomics or proteomics 
approaches (34,35), and studies of obesity and breast cancer have focused mainly on 
changes occurring within the tumor tissue itself (9). Obesity is a pathologic condition 
characterized by systemic inflammation and physiologic changes that affect the body 
globally.  Thus, we took a broader view by investigating a large number of the plasma-
associated factors that revealed associations with obesity:  Our analysis of plasma of 
women at high-risk of breast cancer (susceptible) identified metabolites and proteins that 
potentially drive breast cancer proliferation and aggressiveness andwe validated the 
presence of the same free fatty acids in the plasma of obese post-menopausal women.  
Two proteins commonly found to be highly abundant in breast cancer patients 
SYND1/SCD1 (31) and TNFRSF6b (32), were also found to be elevated in the plasma 
of susceptible subjects. In addition, we showed that the levels of CD160(23), CD27(24), 
IL-12B(25), TNFRSF19 (26), hK8 (27), Nectin4(28), KLK13(29) and CTSV(30) correlated 
with BMI in susceptible individuals but not in healthy controls. Hence, our findings 
supported a number of BMI-associated biochemical changes in plasma from individuals 
with high breast cancer risk.  
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We found that free fatty acids are major factors affecting breast cancer phenotypic 
properties through ERα and mTOR signaling. Our observations are consistent with other 
previously published metabolomics studies that show that same FFA levels are very high 
in the plasma of breast cancer patients and that OA and PA are the free fatty acid released 
in highest amounts from the neighboring adipose tissue of mammary epithelial cells (37-
39,45). It is also possible that increased local estrogen synthesis from adipocytes in the 
mammary gland might also contribute to breast cancer risk, yet we have not identified 
any association with circulating hormone levels.  Consistent with previous studies, we 
found that OA and PA induced changes in cell viability were CD36 dependent (46,47). 
CD36 is the transporter required for unbound FFA uptake into the cell. Unbound FFAs 
are physiologically active, whereas albumin-bound FFAs cannot enter the cells, interact 
with the target molecules. FFA concentrations that elicit observed responses are around 
100 nM, which is typical for what is determined for unbound FFAs in the plasma (as 
opposed to millimolar concentration of albumin bound FFAs) (48). In addition, a recent 
study, targeting the fatty acid receptor CD36 showed that metastasis-initiating cells rely 
on free fatty acids to promote metastasis (49). Of note, the OA levels we measured were 
the third highest in the plasma after PA and SA, and SA was not as effective in inducing 
breast cancer cell proliferation.  
OA induced a significant metabolic reprogramming in breast cancer cells. 
Activation of mTOR signaling provided us with a new metabolic vulnerability point in order 
to target obesity-induced breast cancer using novel ERα ligands that modulate mTOR 
signaling. Previous studies also showed higher mTOR signaling in obesity-associated 
cancers and pathophysiologic conditions (9,50-53). We previously showed that ERα and 
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mTORC1 formed a complex upon activation extranuclear-ER signaling(14). Studies from 
other labs suggests that FFAs activate mTOR signaling by de novo synthesis of 
phosphatidic acid (54,55). Inhibition of mTOR activity by RAD001 blocked p70S6K and 
4EBP1 phosphorylation as well as activation of ERK1 and ERK2 by FFAs. On the other 
hand, inhibition of MEK activity by AZD6244 did not impact mTOR pathway activation, 
further supporting action of FFAs primarily by changing mTOR pathway activity. Using 
metabolite and metabolic phenotype profiling, we showed that OA induced a highly 
energetic phenotype in breast cancer cells, increased glycolytic and aerobic respiration, 
and modulated key metabolic pathways in these cancer cells through activation of mTOR 
and MAPK signaling. Since PaPE-1 targets ERα-mTOR signaling (14), this compound 
resulted in very effective blocking of the OA-induced changes. Our findings have 
established the scientific basis for future preclinical and clinical studies to firmly establish 
the impact of FFAs on ER (+) breast cancer risk and the clinical utility of agents such as 
PaPE1 that target ERα and mTOR signaling in prevention of obesity-associated breast 
cancer. Of note, our data suggested reducing BMI to less than 25 was successful in 
reducing circulating levels of these factors and further emphasized importance of weight 
loss strategies to improve quality of life and reduce comorbidities, including ER(+) breast 
cancer in obese postmenopausal women.  
In conclusion, our clinical data, combined with cell line models and integrated –
omics approaches, provided direct evidence for the mechanistic involvement of FFAs, 
particularly OA, in increasing ERα-(+) breast cancer proliferation and aggressiveness in 
obese postmenopausal women.  Validation of our metabolomics data in several human 
datasets and in cell line models, provides a mechanistic basis for clinically assessing the 
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ability of PaPEs to decrease breast cancer risk in obese postmenopausal women.  
Rewiring of key metabolic pathways by ERα has not been implicated in obesity-
associated breast cancer before. Given the need for better strategies for preventing ER 
(+) breast cancers in obese postmenopausal women, our work offers both novel insights 
and a more complete understanding of the basic mechanisms that underlie the 
association of obesity and breast cancer. Our previous preclinical work, showing benefit 
of PaPE-1 to reduce risk of weight gain and metabolic syndrome associated with loss of 
estrogens(14), combined with our current work highlight an actionable pharmacological 
approach targeting ERα and mTOR signaling that can be exploited for future clinical 
translation. Our findings further emphasize the importance of weight loss strategies to 
reduce comorbidities associated with obesity, including breast cancer.  
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 FIGURE LEGENDS 
Figure 1. Identification of plasma factors from breast cancer susceptible 
women. 
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A. Primary mammary epithelial cultures from women who are BMI<25 (Non-
obese) and BMI>30 (Obese). Keratin 8/18 and Keratin 14 staining was evaluated by 
immunofluorescence. 
B. BMI distribution of samples from age, and racial and ethnic background -matched 
healthy and susceptible individuals (N=40 matched pairs). Paired t-test was used to 
compare BMI for matched healthy and susceptible individuals. 
C. Olink protein biomarker analysis of plasma samples from healthy (N=29) 
and breast cancer susceptible (N=30) postmenopausal women. Protein biomarkers that 
correlate with BMI in susceptible individuals but not healthy controls are shown. A linear 
regression model was generated for BMI and NPX abundance scores of the plasma 
biomarkers. P-values for significance of non-zero slope of fitted lines are indicated for 
susceptible and healthy individuals. 
D. Protein biomarkers that are differentially abundant between susceptible 
vs. healthy individuals were identified by t-test. P-values are indicated.  
E. Top 25 plasma metabolites that distinguish between healthy and 
susceptible individuals from samples in B. was identified using biomarker analysis 
option in web-based MetaboAnalyst software.  
F. Heatmap of the whole metabolite profiling of plasma samples from 
susceptible and healthy individuals. Heatmap was generated using MetaboAnalyst 
software. 
Figure 2. Validating plasma factors associated with obesity. 
A.  63 obese or overweight vs. 37 non-obese postmenopausal women from 
Midlife Women’s Health Study that fits the criteria (BMI>25 obese or overweight, 2-3 
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years into menopause), as measured using GC-MS. Red=BMI>25, Green BMI<25.  
Cluster 3 software was used to process the data. Raw relative concentration data were 
log transformed and metabolites (rows) and plasma samples from each individual 
(columns) were centered to mean. Hierarchical clustering was performed for 
metabolites and plasma samples using uncentered correlation as similarity metric and 
complete linkage as clustering method.  Data are visualized using Java Tree view 
software. In the lower panel, each column represents a patient and each row represents 
a metabolite, with elevated levels in red and reduced levels in blue, and mean control 
levels in white. For BMI and proliferation data, red indicates higher values, whereas 
green indicates lower values.  Bar indicates the log2 scale of coloring for normalized 
metabolite concentrations. 
B. Cell viability assays were performed in both ERα-(+) and ERα-(-) breast 
cancer cell lines. The plasma from 35 obese and 35 non-obese individuals was used to 
treat the cells for seven days before analysis by the WST1 assay. Three technical 
replicates were used. Unpaired t-test was used to assess if plasma from obese vs. non-
obese individuals resulted in statistically significant difference in breast cancer cell line 
viability. Each point is the average of values from three technical replicates treated with 
the same plasma samples.  *, p< 0.05.   
C. Cell migration was tested in BT474 cells treated with the plasma samples 
of 35 obese and 35 non-obese individuals for 24 hours before measurement of cell 
number per field. The mTOR Pathway was found to be activated as indicated by 
increased pS6K activity by plasma from 35 obese individuals but not by plasma from 35 
non-obese individuals in MCF-7 cells.  Each point is the average of values from three 
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technical replicates treated with the same plasma samples.   Unpaired t-test was used 
to assess if plasma from obese vs. non-obese individuals resulted in statistically 
significant difference in breast cancer cell line motility and mTOR pathway activation.  ** 
p< 0.01, *** p< 0.001.  Mean ±SEM is plotted. 
D. Pearson correlation analysis of plasma concentrations of FFAs with MCF-
7 proliferation from 2A. 
E. Metabolomics analysis of Midlife Women’s Health Study-weight loss 
samples. Initial and final visit plasma samples from 21 postmenopausal women from 
Midlife Health Study who met the following criteria was analyzed: BMI>25 at the initial 
visit and BMI<25 at the last visit.  First visit samples (when individuals were obese or 
overweight) are indicated with red-thick lines. 
F. Change in the plasma concentrations of FFAs characterized in 2E. An 
unpaired t-test was used to assess if various FFA treatments resulted in statistically 
significant stimulation of MCF-7 cell proliferation. Individual data points were plotted to 
indicate the change in FFA concentration after weight loss. 
Figure 3. FFAs induces gene expression changes in breast cancer cells 
that are blocked by PaPE-1 
A. Heatmap of RNA-Seq analysis of gene expression changes induced by 
OA, PA, LA and SA. MCF-7 cells were treated with Veh or 100 nM of each FFAs for 
24h. RNA was isolated and sequencing was performed using three samples from each 
treatment group. Differentially expressed genes (DEG) were determined with p <0.05 
and expression fold change >2. 
on July 7, 2020. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2849 
37 
 
B. Principle component analysis (PCA) of gene expression data using DEG 
list from A. 
C. Venn diagram analysis showing overlap of genes up-regulated by different 
FFAs.  
D. Venn diagram analysis showing overlap of genes down-regulated by 
different FFAs.   
E. RNA-Seq analysis of gene expression changes induced by OA and 
OA+PaPE-1. Heat map of the genes with significant changed expression. MCF-7 cells 
were treated with Veh or 100nM OA with and without one µM PaPE-1 for 24 h. RNA 
was isolated and RNA-Seq was performed using two samples from each treatment 
group. Differentially regulated genes were determined with p <0.05 and expression fold 
change >2.  
F. Venn diagram analysis. Venn diagram of the up- and down-regulated 
genes by OA alone or in combination with PaPE-1. 
G. PCA of DEGs from E. 
H. Gene expression values of Clusters from E regulated by OA and reversed 
by PaPE-1. The average gene expression level of the cluster 1 (C1) and 2 (C2) 
identified as PaPE-1 regulated genes.  
I. Examples of OA-regulated genes. Some of the top functions of the 
involved genes are presented 
Figure 4. FFAs activate mTOR and PI3K pathway 
A. Gene set analysis and identification of mTOR and PI3K pathway related 
genes as targets of FFA action. Representative GSEA results and heatmaps for the 
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genes that contribute to the enrichment score. Range of colors (red, pink, light blue, dark 
blue) corresponds to range of expression values (high, moderate, low, lowest).” 
B. Time course of protein phosphorylation induced by FFAs. MCF-7 cells 
were treated with 100 nM OA, PA, LA or SA for 0, 15, 45 or 90 minutes. Protein lysates 
were prepared using RIPA buffer. Phosphorylation and total protein levels of AKT, 
ERK1/ERK2, p70S6K, and 4EBP1 were examined by western blot analysis. β-actin was 
run as internal standard for each blot to ensure equal loading. Antibody signal from 
phosphorylated proteins was normalized relative to the signal from total protein. The 
experiment was repeated two times and representative blots are shown. 
C. Impact of pathway inhibitors on FFA-induced signaling pathway changes. 
MCF-7 cells were pretreated with DMSO vehicle (Ctrl), 1 µM MEK inhibitor, AZD6244 or 
1 µM mTOR inhibitor RAD001 for 30 minutes. Next, cells were treated with 100 nM OA, 
PA, LA or SA for 0, 15 or 45 with or without inhibitors. Protein lysates were prepared 
using RIPA buffer. Phosphorylation and total protein levels of AKT, ERK1/ERK2, 
p70S6K, and 4EBP1 were examined by western blot analysis. The experiment was 
repeated two times and representative blots are shown.   
Figure 5. FFAs induce cell proliferation in an ERα- and CD36-dependent 
manner  
A. Representative GSEA results for OA induced- and cell proliferation-
associated gene sets and heatmaps for the genes that contribute to the enrichment 
score. Range of colors (red, pink, light blue, dark blue) corresponds to range of 
expression values (high, moderate, low, and lowest). 
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B. Cell proliferation of MCF-7 cells in the presence of individual FFAs and 
PaPE-1. Cell proliferation was examined after treatment of cells with free fatty acids at 
100 nM and PaPE-1 at 1 µM. Cells were treated for a week. Six replicates were used in 
each assay, and the experiment was repeated twice. A two-way analysis of variance 
(ANOVA) model was fitted to assess the contribution of ligand (Veh or FFA) and PaPE-
1 treatment on MCF-7 cell proliferation. When the main effects were statistically 
significant at α=0.05, pairwise t-tests with a Bonferroni correction were employed to 
identify if treatment were statistically different from each other. **** p<0.0001. All the 
data from one representative experiment are plotted. 
C. Inhibition of OA-induced MCF-7 cell proliferation by ERα and mTOR 
targeting agents. Cell proliferation was stimulated by 100nM oleic acid and was 
suppressed by adding 1µM Fulvestrant (Fulv), mTOR inhibitor 1µM RAD001, and 1µM 
PaPE-1. In the above cell proliferation experiments, MCF-7 cells were treated in whole 
growth medium adding the designated compounds. The treatment went for 6 days and 
OD at 450 was measured by WST1 assay. The experiment is repeated twice with 6 
technical replicates. A two-way analysis of variance (ANOVA) model was fitted to assess 
the contribution of ligand (Veh or OA) and inhibitor (Ctrl, Fulv, RAD001 and PaPE-1) 
treatment on MCF-7 cell proliferation. When the main effects were statistically significant 
at α=0.05, Sidak’s multiple comparisons test was employed to identify if treatment were 
statistically different from each other. *** p<0.0001. All the data from one representative 
experiment are plotted. 
D. Inhibition of plasma-induced MCF-7 cell proliferation by 4-OH-tam, Fulv 
and PaPE-1.  The MCF-7 cells were treated with Veh, 1µM 4-OH-tam, 1µM Fulv, and 
on July 7, 2020. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2849 
40 
 
1µM PaPE-1 for six days before WST-1 assay in 33% plasma from 63 obese individuals 
(Left) and in standard cell culture with 5% FBS (Right). There are three technical 
replicates for each plasma sample and 14 replicates for each treatment in standard cell 
culture media. A one-way analysis of variance (ANOVA) model was fitted to assess the 
contribution of ligands on plasma- or standard cell culture medium- induced MCF-7 cell 
proliferation. When the main effects were statistically significant at α=0.05, pairwise t-
tests with a Bonferroni correction were employed to identify if treatment were statistically 
different from each other. **** p<0.0001.  
E. Impact of CD36 knock-down on FFA induced cell proliferation in MCF-7 
cells. PPARα was knocked-down using siRNA for 48 hours. Impact on OA and PA 
induced-cell proliferation was assessed using WST-1 assay. Experiment was repeated 
twice with 6 technical replicates. A two-way analysis of variance (ANOVA) model was 
fitted to assess the contribution of ligand (Veh, OA or PA) and siRNA (siCtrl or siCD36) 
treatment on MCF-7 cell proliferation. When the main effects were statistically 
significant at α=0.05, pairwise t-tests with a Bonferroni correction were employed to 
identify if treatment were statistically different from each other. **** p<0.0001. All the 
data from a representative experiment are plotted. 
Figure 6. FFA treatment induces metabolic reprogramming in breast cancer 
cells 
A. Examples of GSEA results of metabolic pathways. Representative GSEA 
results and heatmaps for the genes that contribute to the enrichment score. Range of 
colors (red, pink, light blue, dark blue) corresponds to range of expression values (high, 
moderate, low, lowest).”  
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B. Metabolomics analysis of MCF-7 cells. MCF-7 cells were treated in 
triplicate using Veh, 100 nM OA with/without 1 μM PaPE-1 for 24 hours before harvest 
in cold methanol. Three biological replicates were pooled and submitted for whole 
metabolite analysis. Data are shown for specific metabolic pathways identified by GSEA 
analysis and Metscape plugin of Cytoscape. For glycolysis, fatty acid biosynthesis and 
TCA cycle the levels of affected substrates and their position in the pathway are shown. 
Red indicates upregulation and blue indicates downregulation of the abundance of 
indicated metabolite in the associated pathways. 
C. Cell metabolic phenotype assay using the Seahorse cell energy 
phenotype kit. Cells treated with Veh, OA, and OA+PaPE-1 for 24 hours were tested for 
the energy phenotype at basal level (Left) and under metabolic stress upon inhibition of 
glycolysis or mitochondrial activity (Right). Each experiment was replicated twice with 
three technical replicates. Results from a representative experiment is shown.   
D. OA treatment increase basal and maximal respiration as well as ATP 
production. Mitochondrial energy production was measured using the Mitostress kit. 
Cells were treated in the same way as in Figure 6C. Various mitochondrial respiration 
parameters are calculated as described in Mitostress assay. A two-way analysis of 
variance (ANOVA) model was fitted to assess the contribution of ligands on basal and 
maximal respiration, spare respiration capacity, ATP production and coupling efficiency. 
When the main effects were statistically significant at α=0.05, a Tukey’s multiple 
comparisons test was employed to identify if treatment were statistically different from 
each other. *,p<0.05 ; **,p<0.0001 and **** p<0.0001. Each experiment was replicated 
twice with three technical replicates. Results from a representative experiment is shown. 
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E. OA-dependent mitochondrial respiration changes are mediated through mTOR 
and MAPK signaling pathways. MCF7 cells were treated with 100 nM OA in the presence 
or absence of 1 µM AZD6244 or RAD001 for 24h. Mitochondrial respiration was 
measured using Seahorse Cell energy phenotype kit. A two-way analysis of variance 
(ANOVA) model was fitted to assess the contribution of FFAs to oxygen coupling rate 
(OCR) over time. When the main effects were statistically significant at α=0.05, a 
Dunnet’s multiple comparisons test was employed to identify if treatments were 
statistically different from Veh. *,p<0.05 ;Each experiment was repeated twice with three 
technical replicates. 
F. MCF-7 Cell viability assay in the presence of OA and various metabolic pathway 
inhibitors. MCF-7 cells were treated with Veh or 100 nM OA in the presence or absence 
of 4 µM Etomoxir, 1 mM 2-DG, 50 nM Oligomycin, 20 nM Rotenone or 2 µM UK5099 for 
6 days. Treatments were repeated on day three and cell viability was measured using 
MTS assay on day six. A two-way analysis of variance (ANOVA) model was fitted to 
assess the contribution of inhibitors on OA-induced cell viability. When the main effects 
were statistically significant at α=0.05, a Tukey’s multiple comparisons test was 
employed to identify if treatment were statistically different from each other. **** 
p<0.0001. All the data are plotted. 
Figure 7. FFA treatment induces recruitment of ERα to chromatin 
A. Recruitment of ERα to chromatin in the presence of PaPE-1, OA and 
OA+PaPE-1. MCF-7 cells were treated with Veh and 100 nM OA with or without 1 µM 
PaPE-1 for 45 minutes. ERα-DNA complexes were pulled down using ERα antibodies. 
Three biological replicates were pooled and sequenced. Clustering of ERα binding sites 
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in treatments of Veh (0.1% EtOH), PaPE-1 (1 µM), OA (100 nM), and OA (100 nM) + 
PaPE-1 (1 µM) was done using seqMINER software. Binding sites whose ERα 
occupation increased upon OA treatment are shown. The ERα binding sites were 
separated into four clusters of characteristic patterns: C1, C2, C3 and C4.   
B. Validation of effect of OA and PaPE-1 on the ERα binding at regulatory 
region of PgR, CISH and SREBP1C using ChIP-qPCR. MCF-7 cells were treated with 
Veh and 100 nM OA with or without 1 µM PaPE-1 for 45 minutes. ERα-DNA complexes 
were pulled down using ERα antibodies. Recruitment of ERα to PgR 
(chr11:100,904,522-100,905,458), CISH (chr3:50,642,336-50,643,191) and SREBP1 
(chr17:17,743,329-17,743,912) sites were quantified by Q-PCR. The experiment was 
repeated 3 times with at least duplicates each time. Mean ±SEM is plotted. A one-way 
analysis of variance (ANOVA) model was fitted to assess the contribution of ligand (Veh 
or OA) and inhibitor (Ctrl, PaPE-1) treatment on MCF-7 cell proliferation. When the main 
effects were statistically significant at α=0.05, pairwise t-tests with a Bonferroni 
correction were employed to identify if treatment were statistically different from each 
other. * p<0.05, ** p<0.01. All the data are plotted.   
C. Transcription Factor (TF) binding site enrichment was identified using 
Seqpos tool from Cistrome/Galaxy for clusters of C1, C2, C3 and C4.   
D. Changes in the transcriptional activities of various TFs in the presence of 
OA and OA+PaPE-1. 45 pathway CignalFinder Assay was used to transfect MCF-7 
cells with indicated luciferase construct for 24h. Cells were treated with Veh and 100 nM 
OA with or without 1 µM PaPE-1 for 24 hours before measurement by luciferase assay. 
The experiment was replicated two times with technical duplicatesThe TF activity, TF 
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motif and statistic are shown in detail for PPAR, LXRα, RXR and EGR1. An unpaired t-
test was used to assess the impact of treatment (OA) and inhibitor (PaPE-1) on 
transcription factor activity in MCF-7 cells. * p< 0.05, ** p< 0.01, *** p< 0.001. All the 
data are plotted. 
E. GSEA example of PPARα and SREBP1 target genes that are regulated by 
OA. . Representative GSEA results and heatmaps for the genes that contribute to the 
enrichment score. Range of colors (red, pink, light blue, dark blue) corresponds to 
range of expression values (high, moderate, low, lowest).” 
F. Impact of PPARα (upper panels) or SREBP-1(lower panels) knock-down 
on FFA induced cell proliferation in MCF-7 cells. PPARα and SREBP1 were knocked-
down using siRNA for 48 hours. Impact on OA and PA induced-cell proliferation was 
assessed using WST-1 assay. Experiment was repeated twice with six technical 
replicates. . A two-way analysis of variance (ANOVA) model was fitted to assess the 
contribution of ligand (Veh, OA or PA) and siRNA (siCtrl or siPPARα) treatment on 
MCF-7 cell proliferation. When the main effects were statistically significant at α=0.05, 
pairwise t-tests with a Bonferroni correction were employed to identify if treatment were 
statistically different from each other. **** p<0.0001. All the data are plotted. 
G. Proposed mechanism for obesity-associated postmenopausal ER(+) 
breast cancer. Due to increased lipolysis from adipocytes, circulating FFA levels 
increase in plasma. FFAs are taken up by breast cancer cells in a CD36-dependent 
manner, which results in activation of mTOR and MAPK signaling and ERα recruitment 
to chromatin to increase transcriptional activity of factors that regulate cancer cell 
on July 7, 2020. © 2019 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 12, 2019; DOI: 10.1158/0008-5472.CAN-18-2849 
45 
 
metabolism. Overall, these upstream events increase mitochondrial respiration, cell 
proliferation and aggressiveness for breast cancer cells.  
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